The global weight-loss drug market, once dominated by Novo Nordisk, is undergoing a dramatic transformation. On Friday, the ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the ...

Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the ...

In the marketing effort promoting Lilly’s Mounjaro, Stonestreet and his mother, Jamey, discuss living with type 2 diabetes and taking the GLP-1 for treatment.

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Pharma giant Eli Lilly’s weight loss drug Mounjaro is priced between Rs. 10,000- ₹15,000 in India making it inaccessible to a ...

The county joins municipalities across the country suing Eli Lilly, CVS Caremark, and others for sky-high prices.

Lilly in February announced plans to add four U.S. manufacturing sites at yet-to-be-determined sites as part of a roughly $27 billion investment.

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of the medication.